LONN Lonza Group AG

Lonza Prices EUR 1.2 Billion Dual-Tranche Straight Bonds

Lonza Group AG / Key word(s): Bond
Lonza Prices EUR 1.2 Billion Dual-Tranche Straight Bonds

28.08.2024 / 18:31 CET/CEST


Basel, Switzerland, 28 August 2024 – Lonza Finance International NV, a wholly owned company of Lonza Group Ltd, Basel (“Lonza”), announced today the pricing of its dual tranche EUR 1.2 billion straight bonds. The bonds have a maturity of six and ten years with coupons of 3.25% and 3.50% respectively.

The issuer is Lonza Finance International NV and the bonds will be guaranteed by Lonza. Lonza will apply for the listing of the bonds on the Luxembourg Stock Exchange (Regulated Market). The proceeds of the bonds will be used for general corporate purposes, including the financing of acquisitions and refinancing of existing debt.

Lonza’s issuer rating is currently BBB+ (S&P Global Ratings) with a stable outlook.

A consortium comprising of BofA, Citibank, HSBC, JP Morgan and UBS were mandated to place the bond as Joint Active Bookrunners.


Key Data

 

Six Year Tranche

Ten Year Tranche

Issue Size

EUR 600 million

EUR 600 million

Expected Payment Date 

04 September 2024

04 September 2024

Maturity

04 September 2030

04 September 2034

Issue Price

99.448 percent

98.361 percent

Redemption Price

100 percent

100 percent

Coupon

3.25 percent p.a.

3.50 percent p.a.

 

About Lonza

Lonza is one of the world’s largest healthcare manufacturing organizations. Working across five continents, our global community of around 18,000 colleagues helps pharmaceutical, biotech and nutrition companies to bring their treatments to market. United by our vision to bring any therapy to life, we support our customers with a combination of technological insight, world-class manufacturing, scientific expertise, process excellence and innovation. Our work enables our customers to develop and commercialize their therapeutic discoveries, allowing their patients to benefit from life-saving and life-enhancing treatments.

Our business is structured to meet our customers' complex needs across four divisions: Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients.Our company generated sales of CHF 3.1 billion with a CORE EBITDA of CHF 893 million in Half-Year 2024. Find out more at

Follow @Lonza on
Follow @LonzaGroup on

Lonza Contact Details

Victoria Morgan
Head of External Communications
Lonza Group Ltd

Tel

Daniel Buchta
Head of Investor Relations
Lonza Group Ltd
Tel

Additional Information and Disclaimer
Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.

All trademarks belong to Lonza and are registered in CH, US and/or EU, or belong to their respective third-party owners and are used only for informational purposes.

Privacy Policy



End of Media Release


Language: English
Company: Lonza Group AG
Münchensteinerstrasse 38
4052 Basel
Switzerland
Phone:
Internet:
ISIN: CH0013841017
Valor: 1384101
Listed: SIX Swiss Exchange
EQS News ID: 1977139

 
End of News EQS News Service

1977139  28.08.2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1977139&application_name=news&site_id=research_pool~~~9efe1c65-8ece-4ff7-9608-f21c8e0a38a3
EN
28/08/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Lonza Group AG

 PRESS RELEASE

Lonza Implements its Simplified and Streamlined Operating Model

Lonza Group AG / Key word(s): Miscellaneous Lonza Implements its Simplified and Streamlined Operating Model 01.04.2025 / 14:00 CET/CEST Lonza’s new simplified and streamlined operating model is designed to support its One Lonza vision and strategy Previous divisional structure is now replaced with three newly formed CDMO Business Platforms: Integrated Biologics, Advanced Synthesis, and Specialized Modalities The model comes into effect today, and is reflected on the updated website Basel, Switzerland, 1 April 2025 – Lonza has announced that its new simplified and streamlined o...

 PRESS RELEASE

Lonza Completes its Share Buyback Program

Lonza Group AG / Key word(s): Share Buyback Lonza Completes its Share Buyback Program 01.04.2025 / 07:00 CET/CEST Basel, Switzerland, 1 April 2025 – Lonza today announced the successful completion of its share buyback program of up to CHF 2 billion which was launched on 3 April 2023. Through the program, Lonza repurchased 4,239,731 of its shares on a second trading line on the SIX Swiss Exchange for an average purchase price of CHF 471.7279 per share.The Board of Directors intends to use the capital band to cancel the shares repurchased under the share buyback program. More informa...

Lonza Group AG: 1 director

A director at Lonza Group AG bought 270 shares at 546.082CHF and the significance rating of the trade was 65/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch